CDEK
← All organizations

Vertex

For profitContributed to NMEWebsite ↗

Also known as: Alpine Immune Sciences Inc, A Subsidiary of Vertex | Veratex | Vertex Pharmaceutical Incorporated | Vertex Pharmaceuticals Inc | Vertex Pharmaceuticals Incorporated | VERTEX PHARMS | VERTEX PHARMS INC

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Dec 1, 1998

First marketed drug

May 23, 2011

First NDA

May 23, 2011

Last known activity

Dec 9, 2025

Acquired by Henry Schein, Inc → Watson Pharmaceuticals → Actavis → Allergan PLC (2015) → AbbVie on Jan 1, 1995

Timeline

1980s

  1. Jan 1, 1989

    Vertex— Founded

1990s

  1. Jan 1, 1995

    Henry Schein, Inc— Acquired By

2000s

  1. Jan 1, 2001

    Aurora Biosciences— Acquired

  2. Jan 1, 2009

    ViroChem Pharma— Acquired

2010s

  1. Feb 12, 2018

    tezacaftor— NDA Organization

  2. Feb 12, 2018

    tezacaftor— NDA Secondary Org

  3. Jun 6, 2019

    Exonics— Acquired

  4. Jun 26, 2019

    AbbVie— Now

  5. Sep 3, 2019

    Semma Therapeutics— Acquired

2020s

  1. Jul 11, 2022

    ViaCyteViaCyte— Acquired

  2. Apr 11, 2024

    Alpine Immune Sciences— Acquired

Drugs by trial phase (99 distinct, 282 trials)

Other trials (1 own, 0 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (5)

Subsidiaries (6 direct, 7 total across the full acquisition tree)

Recent trials (50)

Details

Founded
Boston, MA, US Jan 1, 1989
First NDA
May 23, 2011
Last known activity
Dec 9, 2025

Designations held

  • Orphan drug
  • Fast track
  • Priority review
  • Breakthrough therapy

Notes

Acquired Aurora Bioscience 30 Apr 2001